Myriad Genetics's EPS (Basic) for the
three
months ended in Sep. 2024 was $-0.24.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.30.
During the past 3 years, the average EPS without NRIGrowth Rate was -12.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Myriad Genetics's highest 3-Year average EPS without NRI Growth Rate was 26.90% per year. The lowest was -70.20% per year. And the median was -3.15% per year.
Myriad Genetics EPS (Diluted) Historical Data
The historical data trend for Myriad Genetics's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Myriad Genetics's EPS (Diluted)
For the Diagnostics & Research subindustry, Myriad Genetics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics's PE Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's PE Ratio falls into.
Myriad Genetics EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Myriad Genetics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Myriad Genetics EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Myriad Genetics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYGN has been successfully added to your 